Resistance to treatments: <\/p>\n
– Study of resistance mechanisms to anti-HER2 therapy in HER2+ breast cancer and search for therapeutic options <\/p>\n
– Discover the mechanisms of resistance to therapy in triple negative breast cancer and search for alternative therapies <\/p>\n
Metastatic setting: <\/p>\n
– Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy <\/p>\n
– Analysis of postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes <\/p>\n
ER+ breast cancer: <\/p>\n
– Evaluation of the outcomes of single versus double hormone receptor-positive breast cancer <\/p>\n
– Description that the ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4\/6 inhibitors <\/p>\n
– Design of adjuvant endocrine therapy for premenopausal breast cancer <\/p>\n
Breast cancer in very young women: <\/p>\n
– Identification of biomarkers <\/p>\n
– Review of breast cancer in pregnant patients <\/p>\n
Prognostic and prediction: <\/p>\n
– Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer <\/p>\n
– Evaluation of the pathologic complete response rate to neoadjuvant chemotherapy in triple negative breast cancer subtypes <\/p>\n
– Prediction of residual disease after neoadjuvant therapy in HER2-positive breast cancer <\/p>\n
– Study of the incidence, characteristics, and prevention of the alopecia following adjuvant docetaxel <\/p>\n
– Molecular characterization of oligometastatic breast cancer patients<\/p>\n<\/div>\n<\/div><\/div>